Stereotaxis, Inc. (STXS)
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$0.96+13.55%
Close 2026-11-04 · 1-day change
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
QuarterlyIQ Insights · STXS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -61.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 43.5% |
Growth built into the price is above our model estimate.
The price assumes 105.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 11 industry peers
STXS — earnings miss
Dated 2026-08-11
Results of Operations and Financial Condition On August 11, 2026, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2026 second quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein. Forward-Looking Statements and Additional Information Statements are made herein or incorporated herein that are “forward-looki…
Why it matters: Management set a $7 million Q3 target, tied to higher MAGiC catheter output. The result tests the product ramp.
Watch forQ3 recurring revenue is about $7 million or higher.
Also watch forQ3 recurring revenue is below $7 million.
Why it matters: System revenue fell year over year in Q2, when no robot was delivered. Q3 tests whether GenesisX and Synchrony sales lift this line.
Watch forQ3 system revenue is about $3 million or higher.
Also watch forQ3 system revenue is below $3 million.
Why it matters: STXS had $10.5 million in cash at June 30 and lost $3.7 million in free cash flow in Q2. The next report can show whether cash use is easing.
Worry ifThe November 10 report shows negative free cash flow above $3.7 million, or cash below $10.5 million.
Less concerning ifThe report shows negative free cash flow of $3.7 million or less and cash of at least $10.5 million.
Why it matters: Management tied its double-digit growth goal to annual revenue above $40 million. Results can test whether new products offset recent weakness.
Watch forReported 2026 revenue is more than $40 million.
Also watch forReported 2026 revenue is $40 million or less.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$214 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $622 loss on $10,000 · 6.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,042 loss on $10,000 · 70.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company reported negative free cash flow in both Q1 and Q2. A positive result would show progress toward management's stated goal.
Supportive ifA reported quarter in the first half of 2027 has positive free cash flow.
Worry ifFree cash flow remains negative through June 2027.